Cytosorbents Crp (CTSO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytosorbents Crp (CTSO) has a cash flow conversion efficiency ratio of -0.286x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.58 Million) by net assets ($9.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cytosorbents Crp - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Cytosorbents Crp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Cytosorbents Crp for a breakdown of total debt and financial obligations.
Cytosorbents Crp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytosorbents Crp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Advanced Braking Technology Ltd
AU:ABV
|
0.134x |
|
Augwind Energy Tech Storage Ltd
TA:AUGN
|
-0.071x |
|
Altamira Gold Corp
V:ALTA
|
-0.013x |
|
Heramed Ltd
AU:HMD
|
-3.359x |
|
enX Group Ltd
JSE:ENX
|
0.059x |
|
Uniti SA
PA:ALUNT
|
-0.053x |
|
Watos Corea Co. Ltd
KQ:079000
|
0.002x |
|
LAVA THERAP. B.V. EO-12
F:4PKB
|
N/A |
Annual Cash Flow Conversion Efficiency for Cytosorbents Crp (2004–2024)
The table below shows the annual cash flow conversion efficiency of Cytosorbents Crp from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Cytosorbents Crp.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $11.11 Million | $-14.43 Million | -1.299x | -39.62% |
| 2023-12-31 | $23.28 Million | $-21.66 Million | -0.930x | -16.57% |
| 2022-12-31 | $35.37 Million | $-28.23 Million | -0.798x | -256.62% |
| 2021-12-31 | $62.58 Million | $-14.01 Million | -0.224x | -215.84% |
| 2020-12-31 | $79.22 Million | $-5.61 Million | -0.071x | +98.55% |
| 2019-12-31 | $3.42 Million | $-16.76 Million | -4.903x | -666.00% |
| 2018-12-31 | $16.93 Million | $-10.84 Million | -0.640x | -1.68% |
| 2017-12-31 | $10.26 Million | $-6.46 Million | -0.630x | -104.43% |
| 2016-12-31 | $-474.09K | $-6.73 Million | 14.198x | +1393.96% |
| 2015-12-31 | $8.21 Million | $-9.01 Million | -1.097x | +34.72% |
| 2014-12-31 | $3.96 Million | $-6.66 Million | -1.681x | -787.19% |
| 2013-12-31 | $-14.27 Million | $-3.49 Million | 0.245x | -21.37% |
| 2012-12-31 | $-11.63 Million | $-3.62 Million | 0.311x | +102.59% |
| 2011-12-31 | $318.34K | $-3.83 Million | -12.026x | -335.25% |
| 2010-12-31 | $-484.58K | $-2.48 Million | 5.112x | +342.31% |
| 2009-12-31 | $1.27 Million | $-2.67 Million | -2.110x | -110.46% |
| 2008-12-31 | $2.36 Million | $-2.37 Million | -1.002x | -103.98% |
| 2007-12-31 | $-104.30K | $-2.63 Million | 25.196x | +2189.66% |
| 2006-12-31 | $2.36 Million | $-2.85 Million | -1.206x | -299.98% |
| 2005-12-31 | $-82.93K | $-50.00K | 0.603x | -27.65% |
| 2004-12-31 | $-60.00K | $-50.00K | 0.833x | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more